Bowman-Birk inhibitor concentrate suppresses experimental autoimmune neuritis via shifting macrophages from M1 to M2 subtype

Immunology Letters
Tao JinWei Zhu

Abstract

In the present study, we investigated the immuno-regulatory and therapeutic effects of Bowman-Birk inhibitor concentrate (BBIC) on experimental autoimmune neuritis (EAN), an animal model of Guillain-Barré syndrome (GBS) in human. EAN in Lewis rats induced by inoculation with peripheral nerve myelin P0 protein peptide 180-199 (P0 peptide) was treated with BBIC at two different therapeutic regimens. Our data indicated that the administration of BBIC daily orally effectively inhibited and ameliorated the clinical and pathological signs of EAN. The suppression of EAN was associated with an insufficiency of autoreactive T cells, as reflected by inhibited P0 peptide-specific mononuclear cell proliferation and decreased in CD4 and CD8T cells infiltrating into the peripheral nervous system (PNS). BBIC might mediate its therapeutic effects by shifting macrophages from M1 to M2 subtype as evidenced by increasing Arg-1, CD206 and IL-10 and inhibiting IFN-γ, TNF-α, IL-12, iNOS and CD40 expressions on macrophages as well as enhancing anti-inflammatory cytokines IL-4 and IL-10 and decreasing inflammatory cytokines, IFN-γ, TNF-α and IL-17 in the PNS. Our results suggest that BBIC may have therapeutic potential in human GBS and other autoimmun...Continue Reading

References

Apr 3, 2001·Journal of Neuroimmunology·W Pan, A J Kastin
Aug 28, 2001·Brain : a Journal of Neurology·T KornS Jung
Aug 2, 2003·Seminars in Neurology·Bernd C Kieseier, Hans-Peter Hartung
Jun 7, 2007·Digestive Diseases and Sciences·Gary R LichtensteinJeffrey H Ware
Jun 12, 2008·Journal of the Neurological Sciences·Tarik TouilAbdolmohamad Rostami
Nov 26, 2010·Journal of Neurology·Ming-Ou Lu, Jie Zhu
Nov 26, 2010·Journal of Biomedical Materials Research. Part a·Peng Meng Kou, Julia E Babensee
Mar 2, 2012·The Journal of Clinical Investigation·Antonio Sica, Alberto Mantovani
Oct 2, 2012·Experimental and Molecular Pathology·Farinaz Safavi, Abdolmohamad Rostami
Jul 16, 2014·Nature Reviews. Neurology·Bianca van den BergPieter A van Doorn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here